Related Experiment Video
Updated: May 11, 2026
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering
Maria-Cristina S Pranchevicius1, Thiessa R Vieira
1Curso de Medicina; Universidade Federal do Tocantins; Palmas, Brazil.
Abstract:
Cancer is one of the most important health problems because many cases are difficult to prevent. Cancer still has unknown mechanisms of pathogenesis, and its capacity to produce temporary or permanent damage, besides death, is very high. Although many anticancer therapies are available, finding a cure for cancer continues to be a difficult task. Thus, many efforts have been made to develop more effective treatments, such as immunotherapy based on a new class of tumor-specific products that are produced using recombinant DNA technology. These recombinant products are used with the main objectives of killing the tumor and stimulating immune cells to respond to the cancer cells. The principal recombinant products in anticancer therapy are immunostimulants, vaccines, antibodies, immunotoxins and fusion proteins. This review focuses on the general aspects of these genetically engineered products, their clinical performance, current advances and future prospects for this type of anticancer therapy.
Insights
Recombinant DNA technology is advancing cancer treatment through novel immunotherapies. These genetically engineered products, including vaccines and antibodies, aim to destroy tumors and activate immune responses against cancer.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer presents significant prevention and treatment challenges due to complex pathogenesis.
- Existing therapies have limitations, driving the need for innovative approaches.
- Recombinant DNA technology offers a promising avenue for developing advanced cancer treatments.
Purpose of the Study:
- To review genetically engineered products used in anticancer therapy.
- To discuss the clinical performance, advances, and future prospects of these recombinant products.
- To highlight immunotherapy as a key strategy in modern cancer treatment.
Main Methods:
- Review of literature on recombinant DNA technology in cancer therapy.
- Analysis of various recombinant products: immunostimulants, vaccines, antibodies, immunotoxins, and fusion proteins.
- Evaluation of clinical performance and current research trends.
Main Results:
- Recombinant products are engineered to target tumors and stimulate immune responses.
- Key products include immunostimulants, vaccines, antibodies, immunotoxins, and fusion proteins.
- These therapies show potential in enhancing cancer treatment efficacy.
Conclusions:
- Genetically engineered products represent a significant advancement in cancer immunotherapy.
- Continued research and development are crucial for optimizing these treatments.
- Recombinant DNA-based therapies hold promise for improved patient outcomes in oncology.
Related Concept Videos
01:09Recombinant DNA
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:29Microorganisms in Medicine and Therapeutics
01:20The Central Dogma
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...